Who are TIRACIZINE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antivert, Antivert, Dilantin, Zocor, Restoril.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tiracizine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TIRACIZINE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TIRACIZINE (TIRACIZINE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

phase 2 Nuclear receptor subfamily 1 group I member 3 Other Small molecule Live · refreshed every 30 min

Target snapshot

TIRACIZINE (TIRACIZINE).

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TIRACIZINE TARGET	TIRACIZINE		phase 2		Nuclear receptor subfamily 1 group I member 3
Antivert	meclizine	Generic (originally Pfizer/UCB)	marketed	Antihistamine/Antiemetic (vestibular suppressant)	Nuclear receptor subfamily 1 group I member 3, Serine protease hepsin, Histamine H1 receptor	1957-01-01
Antivert	meclozine	Citron Pharma Llc	marketed	Antiemetic	Nuclear receptor subfamily 1 group I member 3	1957-01-01
Dilantin	Phenytoin Sodium	Pfizer	marketed	phenytoin	Nuclear receptor subfamily 1 group I member 3	1953-01-01
Zocor	simvastatin	Merck & Co.	marketed	HMG-CoA Reductase Inhibitor [EPC]	Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Restoril	temazepam	Mallinckrodt	marketed	Benzodiazepine [EPC]	Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-04-26 — Zocor · 10300041 · Formulation · US
2030-02-23 — Zocor · 9597289 · Formulation · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TIRACIZINE — Competitive Intelligence Brief. https://druglandscape.com/ci/tiracizine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing